Desenvolvimento de inibidores do fator VIII na hemofilia A

Chaves, Daniel G; Rodrigues, Cibele V.
Rev. bras. hematol. hemoter ; 31(5): 384-390, 2009.
Artículo en Portugués | LILACS | ID: lil-533596

Documentos relacionados

  1. Inhibitor Formation in Congenital Hemophilia A: an Immunological Perspective.
  2. T cell response to FVIII.
  3. Evaluation of anti-factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents.
  4. Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study.
  5. The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.
  6. Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.
  7. Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells.
  8. SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A.
  9. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment.
  10. Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.